Pharmaceutical composition for oral administration of edaravone and method of administering same
AssigneeK.K. Bcj-94
InventorsHidetoshi SHIMIZU, Yoshinobu NAKAMARU, Yukiko NISHIMURA
Life of this patent
Estimating the term…
Abstract
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
Claims20
A method of treating amyotrophic lateral sclerosis, comprising:
- orally or intragastrically administering a liquid pharmaceutical composition comprising edaravone to a subject in need thereof;
- and
- setting a time interval in a range of 30 minutes or longer to less than 4 hours from the administering of the liquid pharmaceutical composition to a consumption of a meal by the subject in need thereof such that a difference in Cmax is less than 20% with respect to Cmax of a subject fasting for 4 hours or longer after an administration of the liquid pharmaceutical composition in a same time range and/or that a difference in AUC is less than 20% with respect to AUC of the subject fasting for 4 hours or longer after the administration of the liquid pharmaceutical composition in a same time range.
Dependencies are inferred from the claim text.